Lorlatinib and New-Onset Diabetes Practical Monitoring for Oncologists

Patients on lorlatinib require vigilant monitoring for hyperglycemia and ketoacidosis, regardless of pre-existing diabetes risk factors. Proactive screening and early intervention are crucial to mitigate potential severe complications and ensure patient safety.

Infections in Ichthyosis: A Call for Vigilance

Patients with ALOX12B-associated autosomal recessive congenital ichthyosis face significant infectious risks beyond the skin. Clinicians should adopt proactive surveillance and management strategies, including early broad-spectrum antibiotics, to mitigate life-threatening complications.

Health Literacy and Lung Cancer Diagnostic Delays

Patients with limited health literacy experience significant delays in lung cancer diagnosis. This ultimately exacerbates existing health inequities and burdens the healthcare system.

A Systemic Approach to Atopic Dermatitis Treatment Selection

Systemic therapies for atopic dermatitis require careful patient selection and monitoring to maximize benefit and minimize risk. This case highlights the importance of considering disease severity, patient comorbidities, and prior treatment responses when choosing advanced therapies like biologics or small molecule inhibitors.

Lorlatinib and Diabetic Ketoacidosis An Emerging Class Effect?

Patients on lorlatinib should be monitored for hyperglycemia, regardless of autoantibody status. This case raises concerns about potential metabolic toxicities of ALK inhibitors beyond what is currently recognized.